Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptinyx Inc. stock logo
APTX
Aptinyx
$0.10
$0.08
$0.01
$0.72
N/A1.271.32 million shs231,126 shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
-6.6%
$13.48
$14.06
$63.00
$10.00M1.6265,661 shs1.05 million shs
Harrow, Inc. stock logo
HROW
Harrow
$34.93
+11.3%
$29.03
$20.85
$59.23
$1.15B0.41496,857 shs896,400 shs
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$54.99
$54.93
$14.91
$55.19
$1.34B0.03931,731 shsN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00%0.00%0.00%0.00%0.00%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%-99.07%-99.23%-99.45%
Harrow, Inc. stock logo
HROW
Harrow
+11.35%+9.91%+10.50%+45.00%+51.47%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
1.1325 of 5 stars
0.03.00.04.61.11.70.0
Harrow, Inc. stock logo
HROW
Harrow
2.1927 of 5 stars
3.51.00.00.02.02.50.6
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00
N/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
2.50
Moderate BuyN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$63.8382.75% Upside
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GLYC, APTX, HROW, and SRRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Harrow, Inc. stock logo
HROW
Harrow
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$76.00
6/12/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$62.00
6/10/2025
Harrow, Inc. stock logo
HROW
Harrow
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
5/12/2025
Harrow, Inc. stock logo
HROW
Harrow
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $60.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptinyx Inc. stock logo
APTX
Aptinyx
$1MN/AN/AN/A$0.57 per shareN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K1,000.25N/AN/A$0.08 per share1.94
Harrow, Inc. stock logo
HROW
Harrow
$199.61M6.42$0.15 per share229.41$1.95 per share17.91
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$300K4,476.00N/AN/A$6.16 per share8.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptinyx Inc. stock logo
APTX
Aptinyx
-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.56N/A87.33N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/A

Latest GLYC, APTX, HROW, and SRRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01N/AN/AN/A$64.23 millionN/A
5/14/2025Q1 2025
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$5.00-$4.00+$1.00-$0.04N/AN/A
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
1.92
1.92
Harrow, Inc. stock logo
HROW
Harrow
2.01
0.91
0.85
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.02
21.27
21.27

Institutional Ownership

CompanyInstitutional Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
N/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
99.30%

Insider Ownership

CompanyInsider Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
10.97%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
8.70%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
44.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptinyx Inc. stock logo
APTX
Aptinyx
12N/AN/ANot Optionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
5064.53 million58.90 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18036.69 million31.12 millionOptionable
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
10924.42 million13.65 millionOptionable

Recent News About These Companies

New cancer treatment center breaks ground in Redding
Anemia of Inflammation
Sierra Oncology Inc.
2014 GMC Sierra 1500 specs & colors
2017 GMC Sierra 1500
Safety in Radiation Oncology (SAFRON)
2024 GMC Sierra 2500HD
Sierra Coupon for October
Compare 6 trims on the 2021 GMC Sierra 1500

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptinyx stock logo

Aptinyx NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

GlycoMimetics stock logo

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-6.63%)
Closing price 06/13/2025
Extended Trading
$0.16 0.00 (0.00%)
As of 06/13/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Harrow stock logo

Harrow NASDAQ:HROW

$34.93 +3.56 (+11.35%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$35.48 +0.56 (+1.59%)
As of 07/11/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Sierra Oncology stock logo

Sierra Oncology NASDAQ:SRRA

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.